Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Sep 17, 2020 (6 years ago)

Nature-Throid 1 GR

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP deviations; repackaged product was recalled by the manufacturer because it was manufactured under the same conditions as products found to be sub-potent.

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Nature-Throid 1 GR (65 mg), Each Tablet Contains: Thyroid USP 1 GR (65 mg), Liothyronine (T3) 9 mcg, Levothyroxine (T4) 38 mcg, 100 Tablets per bottle, Rx Only, Pkg By PD-Rx Pharmaceuticals Incorporated, Oklahoma City, OK 73127, NDC 43063-819-01.

Affected NDC 43063-0819-01

Compare with the code on your package — it is the most precise check available.

Drug: Levothyroxine Category: Thyroid Medication

Recalling firm
PD-Rx Pharmaceuticals, Inc.
NDC code
43063-819-01
Origin
OK, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0005-2021 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Levothyroxine recalls

See all

Other recalls by PD-Rx Pharmaceuticals, Inc.

All 2020 recalls
Class II · Moderate risk

DULoxetine DR USP

CGMP Deviations: the presence of a Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Duloxetine above the interim acceptable intake limit

Terminated Nitrosamine impurity PD-Rx Pharmaceuticals, Inc. D-0163-2025
Class II · Moderate risk

Glimepiride USP

CGMP deviations.

Terminated cGMP deviation PD-Rx Pharmaceuticals, Inc. NDC 43063-0587-90 D-0559-2023